Humacyte (HUMA) announced that the FDA has granted a full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Shareholder Alert for Humacyte, Inc. (NASDAQ:HUMA)
- Humacyte announces publication of results on ATEV
- HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Humacyte’s sdATEV device shows efficacy in artery bypass trial in primates